Evolus, Inc. (EOLS)

Market Cap	417.87M
Revenue (ttm)	277.94M
Net Income (ttm)	-62.00M
Shares Out	64.69M
EPS (ttm)	-0.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,510,395
Open	6.67
Previous Close	6.72
Day's Range	6.08 - 6.72
52-Week Range	5.71 - 17.44
Beta	1.04
Analysts	Strong Buy
Price Target	21.25 (+228.95%)
Earnings Date	Nov 5, 2025

About EOLS

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 8, 2018
• Employees: 332
• Stock Exchange: NASDAQ
• Ticker Symbol: EOLS
• Website: https://www.evolus.com

Financial Performance

In 2024, Evolus's revenue was $266.27 million, an increase of 31.76% compared to the previous year's $202.09 million. Losses were -$50.42 million, -18.26% less than in 2023.

Analyst Summary

According to 4 analysts, the average rating for EOLS stock is "Strong Buy." The 12-month stock price target is $21.25, which is an increase of 228.95% from the latest price.

Price Target

$21.25

(228.95% upside)

Analyst Consensus: Strong Buy